
PULMONARY HYPERTENSION AND PREGNANCY.

DR KAUMUDI DEVI, DNB RESIDENT, RUBY HALL CLINIC, PUNE. DR MAHAVIR MODI, CONSULTANT PULMONOLOGIST, RUBY HALL CLINIC, PUNE



On examination

- Pulse rate -115 / min
- Blood pressure 110/70 mmhg, right arm supine position
- Respiratory rate 28 cycles /min
- Spo2 88 % room air.
- Afebrile.
- Pallor present.
- No pedal edema.

Covid antigen negative.

started on oxygen via venturi mask, 50 % fio2, 12 L o2, saturation improved to 96 %.

admitted as covid suspect in ICU.

CHEST RADIOGRAPH

ECG

Sex:M		th date:		year			
cm Medications Symptoms: Historys Vent, rate PR:rnt ORS.dur OT/OTe(E) int P/ORS/T dkis RV5/SV1 amp	43/	112 n 76 n 362/ 411 n 88/ 254 • 29/ 1.00 n	sam 15 15 15		2210 4012 4664 9150	Sinus rhythm Short PR interval Moderate ST deprass Twave abnormality. ** abnormal ECG *	and the second second second second
RV5+SV1 amp		2.29 1	IV III		Revis	firmed Report	
10 mm/m¥ 25 i	nwr∕s F	ilter: H5D	D 25 Hz 10 I	rm∕mV	5 mm/n	-v	10
James James			s		AL A		v
					v2		
1-1-							
	-		-				
Rhythm[11] 10 m	m/mV	t F			Marris Transferrer		



- PH- 7.434
- PCO2 27
- PO2 85
- HCO3 18


D dimer - 761 PT - 12.7		
INR 1.07		D dimer - 761


DIFFERENTIAL DIAGNOSIS

Acute Pulmonary Embolism. Covid – 19 pneumonia

Acute Asthma exacerbation

HRCT thorax done which showed subpleural consolidation and GGO in right lower lobe, GGO in bilateral upperlobe along with dilated pulmonary artery.





2-D ECHO

- LVEF 60 %.
- PASP 90-100 mmhg.
- RA / RV grossly dilated.
- RV hypertrophy present.
- No evidence of clot/ embolism.
- No valvular abnormality.




Lower limb venous doppler

• No evidence of DVT .

• Started on clexane.

CTPA - no evidence of pulmonary embolism.






MALE NAIDU MADAM

Palpitations : 2nd month of pregnancy

2D ECHO

ECG



2D ECHO & COLOR DOPPLER Levocardia, viscero-atrial situs solitus Intact interatrial and Interventricular septum Normally related great vessels Normal pulmonary and systemic venous drainage All cardiac chambers are normal sized Normal Diastolic filling patterns No regional wall motion abnormality No regional wall motion abnormality Mitral, Aortic, Tricuspid and pulmonary valves are structurally and functionally normal No pulmonary hypertension Left sided Aortic Arch / No COA Normal pericardium

DOPPLER

MEASURMENTS


MMODE	
Ao Diam	2.3 cm
	2.6 cm
LA Diam	1.15
LA/Ao	
Ao/LA	0.87
IVSd	0.8 cm
LVIDd	3.5 cm
EDV(Teich)	52 ml
LVPWd	0.7 cm
IVSs	1.1 cm
LVIDs	2.4 cm
ESV(Teich)	20 ml
EF(Teich)	62 %
%FS	32 %
LVPWs	1.1 cm

IMPRESSION

All cardiac chambers are normal sized Normal diastolic filling patterns No regional wall motion abnormality Normal valves Normal Biventricular function No pericardial effusion/clots/vegetations No pulmonary hypertension


AN

Connective tissue workup



- Protein C normal
- Protein S 35 (lower side) →
 S/O high risk of embolism
- APCR-V ratio

 No portal hypertension. 	Not done : severe pulmonary hypertension	Report awaited
USG abdomen	TEE	Genetic mutation of BMPR2



No splenectomy

thyroid status normal

miscellaneous

no evidence of tumour

no evidence of vasculitis

- Started on tadalafil 20 mg OD .
- started on clexane 0.6 ml OD.
 - Developed rashes and drop in platelet count : clexane stopped.
- O2 tapered to NC 4L: spO2 92 %

Repeat 2-d echo after 1 week

RA/RV DILATED PASP 112 mmhg, EF- 55-60 %. Good RV function..

- A multi disciplinary approach was taken with obstetrician, cardiologist, pulmonologist.
- <u>Decision taken to continue pregnancy</u> as patient was not having any failure symptoms.
- monitoring NT-pro BNP, electrolytes and 2-D echo once in 5 days
- Tab macitent 10 mg added
 - Considering risk to benefit ratio
 - organogenesis period was completed.

DATE	ECHO - PASP	NT-PRO BNP
2/11	112	270
9/11	115	115
13/11	107	387
17/11	148	474
23/11	135	993

- Tab tadalafil 20 mg OD,
- macitentan 10 mg OD,
- digoxin 0.25 mg OD,
- Clexane 0.4 ml OD,
- Dytor 20 mg OD.

- Hemoptysis again at 32 weeks of gestation.
- O2 requirement increased to 15 L via venturi mask 50 %.

Hence decided to plan for LSCS Explained the risk of sudden drop in PASP, pulmonary edema SOS need for ECMO.

- Post LSCS, patient was stable.
- Her oxygen requirement reduced to 2 L via nasal canula.
- She required norad for 16 hours, tapered and stopped.

Post LSCS,

- V/Q scan showed low probability of embolism.
- Riociguat started
 - After cardiac opinion
- Tab selexipag 400 mg od , followed by 800mg tablet OD

Recent 2-D echo

- PASP 90 mmhg
- Gross RA/RV dilatation present.
- Good RV function.

Baby details.

complete white out lungs, intubated, given surfactant, and extubated within 2 days, maintained on bottle CPAP for 1.5 weeks, followed by reducing FiO2 continously and progressively, taken on room air on 14 th day.

> Baby had PDA , advised medical closure with sildenafil.

> > After 2 weeks, PDA closure done.

- Patient is on 2 L nasal o2, maintains spo2 of 96 %.
- Bp 100/60

LINE OF TREATMENT

- Oxygen , 1-2 L /minute.
- Diuretics dytor 20 mg OD.
- Macitentan 10 mg OD.
- Selexipag 800 mg OD
- Riociguat 2mg TDS.
- Lanoxin 0.25 mg 1/2 OD for 6 days in a week.
- Ivabrad 5 mg 1/2 BD.
- Xarelto 15 mg OD.

 Pulmonary hypertension is associated with high mortality and morbidity risks for the mother. The risk is increased in all groups of pulmonary hypertension (1 to 5). Although women with severe pulmonary hypertension seem to be at higher risk, a safe cut-off value is not known.

- Pregnancy in women with pulmonary hypertension (PH) is known to be associated with significantly high morbidity and mortality rates, with an estimated mortality between 30% and 56%.
- The physiological changes that occur during pregnancy and the peripartum period are poorly tolerated.
- During pregnancy, an index of suspicion should exist for common conditions associated with pregnancy that can be complicated by PH, as these need to be evaluated thoroughly during this critical period.
- These include pulmonary and amniotic fluid embolisms, which are very common and mostly fatal. Most of the maternal PH-associated deaths occur during labor or within 1 month post-delivery.